Readings Newsletter
Become a Readings Member to make your shopping experience even easier.
Sign in or sign up for free!
You’re not far away from qualifying for FREE standard shipping within Australia
You’ve qualified for FREE standard shipping within Australia
The cart is loading…
This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.
Enhancing Aspirin Repositioning with Cisplatin in Glioma is a comprehensive book written by Abirami M P, which explores the potential of using aspirin and cisplatin in combination as an effective treatment for glioma, a type of brain cancer.The book provides a detailed molecular study of the mechanisms by which aspirin and cisplatin work together to induce cell death in glioma cells. Abirami M P highlights the benefits of repositioning aspirin, a widely used anti-inflammatory drug, in combination with cisplatin, a potent anticancer drug, for the treatment of glioma.The book also discusses the challenges associated with the development of effective therapies for glioma and how the use of aspirin and cisplatin can help overcome these challenges. Abirami M P provides a thorough analysis of the current research in the field and offers insights into the future directions of research.
The book is written in a clear and concise manner, making it accessible to a wide range of readers, including researchers, clinicians, and students in the field of oncology. It provides a valuable resource for those interested in understanding the potential of aspirin and cisplatin in the treatment of glioma and other types of cancer. Overall, Enhancing Aspirin Repositioning with Cisplatin in Glioma is an essential read for anyone interested in the latest advancements in cancer treatment research.
$9.00 standard shipping within Australia
FREE standard shipping within Australia for orders over $100.00
Express & International shipping calculated at checkout
This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.
Enhancing Aspirin Repositioning with Cisplatin in Glioma is a comprehensive book written by Abirami M P, which explores the potential of using aspirin and cisplatin in combination as an effective treatment for glioma, a type of brain cancer.The book provides a detailed molecular study of the mechanisms by which aspirin and cisplatin work together to induce cell death in glioma cells. Abirami M P highlights the benefits of repositioning aspirin, a widely used anti-inflammatory drug, in combination with cisplatin, a potent anticancer drug, for the treatment of glioma.The book also discusses the challenges associated with the development of effective therapies for glioma and how the use of aspirin and cisplatin can help overcome these challenges. Abirami M P provides a thorough analysis of the current research in the field and offers insights into the future directions of research.
The book is written in a clear and concise manner, making it accessible to a wide range of readers, including researchers, clinicians, and students in the field of oncology. It provides a valuable resource for those interested in understanding the potential of aspirin and cisplatin in the treatment of glioma and other types of cancer. Overall, Enhancing Aspirin Repositioning with Cisplatin in Glioma is an essential read for anyone interested in the latest advancements in cancer treatment research.